| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $499,759 ) |
| | 2024 | 2024 | CERTARA UK LIMITED | LEVEL 2-ACERO - 1 CONCOURSE WAY - SOUTH YORKSHIRE | SHEFFIELD | | | | GBR | U01FD007904 | A State-of-the-Art Virtual Bioequivalence Platform and Case Studies on Complex Formulations, Systemic and Local Concentration-based Bioequivalence | 002 | 2 | FDA | 8/27/2024 | $249,837 |
| | 2024 | 2024 | CERTARA UK LIMITED | LEVEL 2-ACERO - 1 CONCOURSE WAY - SOUTH YORKSHIRE | SHEFFIELD | | | | GBR | U01FD007954 | Formulation toolbox for topically applied drugs to account for physical parameters, dynamic metamorphosis and influence of excipients | 002 | 2 | FDA | 8/28/2024 | $249,922 |
| | 2024 | 2023 | CERTARA UK LIMITED | LEVEL 2-ACERO - 1 CONCOURSE WAY - SOUTH YORKSHIRE | SHEFFIELD | | | | GBR | U01FD007954 | Formulation toolbox for topically applied drugs to account for physical parameters, dynamic metamorphosis and influence of excipients | 001 | 1 | FDA | 3/8/2024 | $249,996 |
| | 2024 | 2023 | CERTARA UK LIMITED | LEVEL 2-ACERO - 1 CONCOURSE WAY - SOUTH YORKSHIRE | SHEFFIELD | | | | GBR | U01FD007904 | A State-of-the-Art Virtual Bioequivalence Platform and Case Studies on Complex Formulations, Systemic and Local Concentration-based Bioequivalence | 001 | 1 | FDA | 3/8/2024 | $249,980 |
| | 2024 | 2023 | CERTARA UK LIMITED | LEVEL 2-ACERO - 1 CONCOURSE WAY - SOUTH YORKSHIRE | SHEFFIELD | | | | GBR | U01FD007954 | Formulation toolbox for topically applied drugs to account for physical parameters, dynamic metamorphosis and influence of excipients | 000 | 1 | FDA | 2/26/2024 | -$249,996 |
| | 2024 | 2023 | CERTARA UK LIMITED | LEVEL 2-ACERO - 1 CONCOURSE WAY - SOUTH YORKSHIRE | SHEFFIELD | | | | GBR | U01FD007904 | A State-of-the-Art Virtual Bioequivalence Platform and Case Studies on Complex Formulations, Systemic and Local Concentration-based Bioequivalence | 000 | 1 | FDA | 2/26/2024 | -$249,980 |
| | 2024 | 2022 | CERTARA UK LIMITED | LEVEL 2-ACERO - 1 CONCOURSE WAY - SOUTH YORKSHIRE | SHEFFIELD | | | | GBR | U01FD007323 | Progressing integration of in vitro topical formulation characterisation, release and permeation data to the next level - PBPK based extrapolation to bioequivalence assessment in virtual populations | 000 | 2 | FDA | 7/18/2024 | $0 |
| | 2024 | 2019 | CERTARA UK LIMITED | LEVEL 2-ACERO - 1 CONCOURSE WAY - SOUTH YORKSHIRE | SHEFFIELD | | | | GBR | U01FD006521 | Characterization of key system parameters of mechanistic dermal PBPK models in various skin diseases and performance verification of the model using observed local and systemic concentrations | 000 | 2 | FDA | 9/25/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $499,976 ) |
| | 2023 | 2023 | CERTARA UK LIMITED | LEVEL 2-ACERO - 1 CONCOURSE WAY - SOUTH YORKSHIRE | SHEFFIELD | | | | GBR | U01FD007904 | A State-of-the-Art Virtual Bioequivalence Platform and Case Studies on Complex Formulations, Systemic and Local Concentration-based Bioequivalence | 002 | 1 | FDA | 9/27/2023 | -$249,980 |
| | 2023 | 2023 | CERTARA UK LIMITED | LEVEL 2-ACERO - 1 CONCOURSE WAY - SOUTH YORKSHIRE | SHEFFIELD | | | | GBR | U01FD007904 | A State-of-the-Art Virtual Bioequivalence Platform and Case Studies on Complex Formulations, Systemic and Local Concentration-based Bioequivalence | 001 | 1 | FDA | 9/25/2023 | $0 |
| | 2023 | 2023 | CERTARA UK LIMITED | LEVEL 2-ACERO - 1 CONCOURSE WAY - SOUTH YORKSHIRE | SHEFFIELD | | | | GBR | U01FD007904 | A State-of-the-Art Virtual Bioequivalence Platform and Case Studies on Complex Formulations, Systemic and Local Concentration-based Bioequivalence | 003 | 1 | FDA | 9/28/2023 | $249,980 |
| | 2023 | 2023 | CERTARA UK LIMITED | LEVEL 2-ACERO - 1 CONCOURSE WAY - SOUTH YORKSHIRE | SHEFFIELD | | | | GBR | U01FD007954 | Formulation toolbox for topically applied drugs to account for physical parameters, dynamic metamorphosis and influence of excipients | 001 | 1 | FDA | 9/25/2023 | $0 |
| | 2023 | 2023 | CERTARA UK LIMITED | LEVEL 2-ACERO - 1 CONCOURSE WAY - SOUTH YORKSHIRE | SHEFFIELD | | | | GBR | U01FD007954 | Formulation toolbox for topically applied drugs to account for physical parameters, dynamic metamorphosis and influence of excipients | 002 | 1 | FDA | 9/27/2023 | -$249,996 |
| | 2023 | 2023 | CERTARA UK LIMITED | LEVEL 2-ACERO - 1 CONCOURSE WAY - SOUTH YORKSHIRE | SHEFFIELD | | | | GBR | U01FD007954 | Formulation toolbox for topically applied drugs to account for physical parameters, dynamic metamorphosis and influence of excipients | 000 | 1 | FDA | 8/16/2023 | $249,996 |
| | 2023 | 2023 | CERTARA UK LIMITED | LEVEL 2-ACERO - 1 CONCOURSE WAY - SOUTH YORKSHIRE | SHEFFIELD | | | | GBR | U01FD007954 | Formulation toolbox for topically applied drugs to account for physical parameters, dynamic metamorphosis and influence of excipients | 003 | 1 | FDA | 9/28/2023 | $249,996 |
| | 2023 | 2023 | CERTARA UK LIMITED | LEVEL 2-ACERO - 1 CONCOURSE WAY - SOUTH YORKSHIRE | SHEFFIELD | | | | GBR | U01FD007904 | A State-of-the-Art Virtual Bioequivalence Platform and Case Studies on Complex Formulations, Systemic and Local Concentration-based Bioequivalence | 000 | 1 | FDA | 8/24/2023 | $249,980 |
| | 2023 | 2022 | CERTARA UK LIMITED | LEVEL 2-ACERO - 1 CONCOURSE WAY - SOUTH YORKSHIRE | SHEFFIELD | | | | GBR | U01FD007323 | Progressing integration of in vitro topical formulation characterisation, release and permeation data to the next level - PBPK based extrapolation to bioequivalence assessment in virtual populations | 001 | 2 | FDA | 7/12/2023 | $0 |
| | 2023 | 2022 | CERTARA UK LIMITED | LEVEL 2-ACERO, 1 CONCOURSE WAY, | SHEFFIELD | SOUTH YORKSHIRE | | | GBR | U01FD007323 | Progressing integration of in vitro topical formulation characterisation, release and permeation data to the next level - PBPK based extrapolation to bioequivalence assessment in virtual populations | 000 | 2 | FDA | 10/18/2022 | $0 |
| | 2023 | 2019 | CERTARA UK LIMITED | LEVEL 2-ACERO - 1 CONCOURSE WAY - SOUTH YORKSHIRE | SHEFFIELD | | | | GBR | U01FD006521 | Characterization of key system parameters of mechanistic dermal PBPK models in various skin diseases and performance verification of the model using observed local and systemic concentrations | 000 | 2 | FDA | 2/8/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $249,941 ) |
| | 2022 | 2022 | CERTARA UK LIMITED | LEVEL 2-ACERO, 1 CONCOURSE WAY, | SHEFFIELD | SOUTH YORKSHIRE | | | GBR | U01FD007323 | Progressing integration of in vitro topical formulation characterisation, release and permeation data to the next level - PBPK based extrapolation to bioequivalence assessment in virtual populations | 000 | 2 | FDA | 7/22/2022 | $249,941 |
| | 2022 | 2019 | CERTARA UK LIMITED | LEVEL 2-ACERO, 1 CONCOURSE WAY, | SHEFFIELD | SOUTH YORKSHIRE | | | GBR | U01FD006521 | Characterization of key system parameters of mechanistic dermal PBPK models in various skin diseases and performance verification of the model using observed local and systemic concentrations | 000 | 2 | FDA | 11/9/2021 | $0 |
| | 2022 | 2019 | CERTARA UK LIMITED | LEVEL 2-ACERO, 1 CONCOURSE WAY, | SHEFFIELD | SOUTH YORKSHIRE | | | GBR | U01FD006521 | Characterization of key system parameters of mechanistic dermal PBPK models in various skin diseases and performance verification of the model using observed local and systemic concentrations | 001 | 2 | FDA | 2/25/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $249,891 ) |
| | 2021 | 2021 | CERTARA UK LIMITED | LEVEL 2-ACERO, 1 CONCOURSE WAY, | SHEFFIELD | SOUTH YORKSHIRE | | | GBR | U01FD007323 | Progressing integration of in vitro topical formulation characterisation, release and permeation data to the next level - PBPK based extrapolation to bioequivalence assessment in virtual populations | 000 | 1 | FDA | 8/4/2021 | $249,891 |
| | 2021 | 2017 | CERTARA UK LIMITED | LEVEL 2-ACERO, 1 CONCOURSE WAY, | SHEFFIELD | SOUTH YORKSHIRE | | | GBR | U01FD005865 | Design, Development, Implementation and Validation of a Mechanistic Physiologically-based Pharmacokinetic (PBPK) Framework for the Prediction of the In Vivo Behaviour of Supersaturating Drug Products | 000 | 2 | FDA | 2/2/2021 | $0 |
| | 2021 | 2016 | CERTARA UK LIMITED | LEVEL 2-ACERO, 1 CONCOURSE WAY, | SHEFFIELD | SOUTH YORKSHIRE | | | GBR | U01FD005225 | Development and validation of dermal PBPK modelling platform towards virtual bioequivalence assessment considering population variability | 000 | 3 | FDA | 3/25/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $0 ) |
| | 2020 | 2019 | CERTARA UK LIMITED | LEVEL 2-ACERO, 1 CONCOURSE WAY, | SHEFFIELD | SOUTH YORKSHIRE | S1 2BJ | | GBR | U01FD006521 | Characterization of key system parameters of mechanistic dermal PBPK models in various skin diseases and performance verification of the model using observed local and systemic concentrations | 001 | 2 | FDA | 10/30/2019 | -$137,864 |
| | 2020 | 2019 | CERTARA UK LIMITED | LEVEL 2-ACERO, 1 CONCOURSE WAY, | SHEFFIELD | SOUTH YORKSHIRE | S1 2BJ | | GBR | U01FD006521 | Characterization of key system parameters of mechanistic dermal PBPK models in various skin diseases and performance verification of the model using observed local and systemic concentrations | 003 | 2 | FDA | 8/13/2020 | $0 |
| | 2020 | 2019 | CERTARA UK LIMITED | LEVEL 2-ACERO, 1 CONCOURSE WAY, | SHEFFIELD | SOUTH YORKSHIRE | S1 2BJ | | GBR | U01FD006521 | Characterization of key system parameters of mechanistic dermal PBPK models in various skin diseases and performance verification of the model using observed local and systemic concentrations | 002 | 2 | FDA | 3/13/2020 | $0 |
| | 2020 | 2019 | CERTARA UK LIMITED | LEVEL 2-ACERO, 1 CONCOURSE WAY, | SHEFFIELD | SOUTH YORKSHIRE | S1 2BJ | | GBR | U01FD006521 | Characterization of key system parameters of mechanistic dermal PBPK models in various skin diseases and performance verification of the model using observed local and systemic concentrations | 000 | 2 | FDA | 10/23/2019 | $137,864 |
|
| Issue Date FY: 2019 ( Subtotal = $249,406 ) |
| | 2019 | 2019 | CERTARA UK LIMITED | LEVEL 2-ACERO, 1 CONCOURSE WAY, | SHEFFIELD | SOUTH YORKSHIRE | S1 2BJ | | GBR | U01FD006521 | Characterization of key system parameters of mechanistic dermal PBPK models in various skin diseases and performance verification of the model using observed local and systemic concentrations | 001 | 2 | FDA | 7/19/2019 | $249,406 |
| | 2019 | 2018 | CERTARA UK LIMITED | LEVEL 2-ACERO, 1 CONCOURSE WAY, | SHEFFIELD | SOUTH YORKSHIRE | S1 2BJ | | GBR | U01FD006521 | Characterization of key system parameters of mechanistic dermal PBPK models in various skin diseases and performance verification of the model using observed local and systemic concentrations | 000 | 1 | FDA | 7/19/2019 | $0 |
| | 2019 | 2017 | CERTARA UK LIMITED | LEVEL 2-ACERO, 1 CONCOURSE WAY, | SHEFFIELD | SOUTH YORKSHIRE | S1 2BJ | | GBR | U01FD005865 | Design, Development, Implementation and Validation of a Mechanistic Physiologically-based Pharmacokinetic (PBPK) Framework for the Prediction of the In Vivo Behaviour of Supersaturating Drug Products | 000 | 2 | FDA | 4/10/2019 | $0 |
| | 2019 | 2017 | CERTARA UK LIMITED | LEVEL 2-ACERO, 1 CONCOURSE WAY, | SHEFFIELD | SOUTH YORKSHIRE | S1 2BJ | | GBR | U01FD005865 | Design, Development, Implementation and Validation of a Mechanistic Physiologically-based Pharmacokinetic (PBPK) Framework for the Prediction of the In Vivo Behaviour of Supersaturating Drug Products | 001 | 2 | FDA | 6/25/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $249,443 ) |
| | 2018 | 2018 | CERTARA UK LIMITED | LEVEL 2-ACERO, 1 CONCOURSE WAY, | SHEFFIELD | SOUTH YORKSHIRE | S1 2BJ | | GBR | U01FD006521 | Characterization of key system parameters of mechanistic dermal PBPK models in various skin diseases and performance verification of the model using observed local and systemic concentrations | 001 | 1 | FDA | 8/29/2018 | -$249,443 |
| | 2018 | 2018 | CERTARA UK LIMITED | LEVEL 2-ACERO, 1 CONCOURSE WAY, | SHEFFIELD | SOUTH YORKSHIRE | S1 2BJ | | GBR | U01FD006521 | Characterization of key system parameters of mechanistic dermal PBPK models in various skin diseases and performance verification of the model using observed local and systemic concentrations | 000 | 1 | FDA | 8/27/2018 | $249,443 |
| | 2018 | 2018 | CERTARA UK LIMITED | LEVEL 2-ACERO, 1 CONCOURSE WAY, | SHEFFIELD | SOUTH YORKSHIRE | S1 2BJ | | GBR | U01FD006521 | Characterization of key system parameters of mechanistic dermal PBPK models in various skin diseases and performance verification of the model using observed local and systemic concentrations | 001 | 1 | FDA | 8/29/2018 | $249,443 |
| | 2018 | 2017 | SIMCYP LTD | BLADES ENTERPRISE CENTRE | SHEFFIELD | SOUTH YORKSHIRE | S2 4SU | | GBR | U01FD005865 | Design, Development, Implementation and Validation of a Mechanistic Physiologically-based Pharmacokinetic (PBPK) Framework for the Prediction of the In Vivo Behaviour of Supersaturating Drug Products | 000 | 2 | FDA | 10/25/2017 | $0 |
| | 2018 | 2017 | CERTARA UK LIMITED | LEVEL 2-ACERO, 1 CONCOURSE WAY, | SHEFFIELD | SOUTH YORKSHIRE | S1 2BJ | | GBR | U01FD005865 | Design, Development, Implementation and Validation of a Mechanistic Physiologically-based Pharmacokinetic (PBPK) Framework for the Prediction of the In Vivo Behaviour of Supersaturating Drug Products | 001 | 2 | FDA | 7/18/2018 | $0 |
| | 2018 | 2017 | CERTARA UK LIMITED | LEVEL 2-ACERO, 1 CONCOURSE WAY, | SHEFFIELD | SOUTH YORKSHIRE | S1 2BJ | | GBR | U01FD005865 | Design, Development, Implementation and Validation of a Mechanistic Physiologically-based Pharmacokinetic (PBPK) Framework for the Prediction of the In Vivo Behaviour of Supersaturating Drug Products | 002 | 2 | FDA | 8/16/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $284,895 ) |
| | 2017 | 2017 | SIMCYP LTD | BLADES ENTERPRISE CENTRE | SHEFFIELD | SOUTH YORKSHIRE | S2 4SU | | GBR | U01FD005865 | Design, Development, Implementation and Validation of a Mechanistic Physiologically-based Pharmacokinetic (PBPK) Framework for the Prediction of the In Vivo Behaviour of Supersaturating Drug Products | 000 | 2 | FDA | 8/9/2017 | $284,895 |
| | 2017 | 2016 | SIMCYP LTD | BLADES ENTERPRISE CENTRE | SHEFFIELD | SOUTH YORKSHIRE | S2 4SU | | GBR | U01FD005225 | Development and validation of dermal PBPK modelling platform towards virtual bioequivalence assessment considering population variability | 000 | 3 | FDA | 1/31/2017 | $0 |
| | 2017 | 2016 | SIMCYP LTD | BLADES ENTERPRISE CENTRE | SHEFFIELD | SOUTH YORKSHIRE | S2 4SU | | GBR | U01FD005225 | Development and validation of dermal PBPK modelling platform towards virtual bioequivalence assessment considering population variability | 001 | 3 | FDA | 7/28/2017 | $0 |
|
|
